41 results on '"Port, Kerstin"'
Search Results
2. Daily Low-Volume Paracentesis and Clinical Complications in Patients With Refractory Ascites
3. Liver stiffness measurement as a non-invasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
4. Improvements in ALT levels during Bulevirtide treatment for hepatitis D are seen regardless of virologic response
5. Unusual HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients
6. Five years follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D
7. Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA
8. Treating hepatitis D with bulevirtide – Real-world experience from 114 patients
9. Kinetics and predictive value of HBcrAg , HBV RNA and anti‐HBc during bulevirtide treatment of chronic HDV ‐infected patients
10. Qualitiy of life-scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: an analysis of the HIDIT-II trial
11. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial
12. Baseline bile acid levels but not bile acid increases during bulevirtide treatment of hepatitis D are associated with HDV RNA decline
13. Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience
14. Bulevirtide 2 mg/day monotherapy in patients with chronic hepatitis delta with or without cirrhosis: a multicenter european cohort real-life study
15. Imprint of unconventional T cell response in acute hepatitis C persists despite successful early antiviral treatment
16. Distinct Immune Imprints of Post–Liver Transplantation Hepatitis C Persist Despite Viral Clearance
17. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy
18. Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients
19. Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C
20. Imprints of post-liver transplantation: HCV recurrence on immune cell compartment persist despite achieving therapy-induced SVR
21. Liver stiffness across different chronic liver disease under therapy with statin in a real life cohort
22. Frequency of Potential Drug–Drug Interactions in the Changing Field of HCV Therapy
23. Letter: a 5-year long-term follow-up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis
24. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses
25. FRI-175-Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study
26. PS-030-Cure of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T-cell responses
27. THU-178-Drug-drug interactions in HCV therapy: Still relevant for clinical practice?
28. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial
29. Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?
30. Real-world effect of ribavirin on quality of life in HCV-infected patients receiving interferon-free treatment
31. Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up
32. Home-based drainage of refractory ascites by a permanent-tunneled peritoneal catheter can safely replace large-volume paracentesis
33. Antiviral treatment and liver‐related complications in hepatitis delta
34. Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B
35. Drug–Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort
36. Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders
37. Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting
38. Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease
39. Effects of HDV infection and pegylated interferon α treatment on the natural killer cell compartment in chronically infected individuals
40. Compromised Function of Natural Killer Cells in Acute and Chronic Viral Hepatitis
41. Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.